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SUMMARY
Cell-free and concentrated ascites reinfusion therapy（CART）is an effective and safe therapy for
patients with refractory ascites or pleural effusion. CART was initially indicated for cirrhotic asci-
tes, and has come to be widely used for malignant ascites. Recently, cancer therapy that applies
cancer cells obtained by filtration process is considered, and CART attracts attention as one of the im-
portant therapies to support future cancer therapy. However, the numbers of CART in Japan is not
sufficient because the equipment for CART is high price and large. Additionally, the specialized me-
dical staff such as clinical engineers is necessary for CART because of complicated operation. The-
refore, we think that development of next-generation type equipment for CART that can be per-
formed safely, easily, and reliably is necessary. We could develop the exclusive equipment for
CART according to the project management by multifarious worker cooperation in five years.
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